News

MetaVia's DA-1726 reaches highest doses in Phase 1 study with 9.1% mean body weight loss at eight weeks, ahead...

Vivani Medical completes dosing in Phase 1 trial of semaglutide implant designed to deliver the weight-loss drug continuously for...

Vistagen's fasedienol Phase 2 data for social anxiety disorder readout set for August 2026 will determine next steps in...

FDA approves Tudriqev for anti-PD-1 resistant advanced melanoma, offering a new oncolytic viral therapy option for patients who failed...

TN-201 gene therapy reduces hypertrophy in all six evaluable HCM patients in MyPEAK-1 trial, targeting MYBPC3 mutation root cause.

Summit Therapeutics launches HARMONi-GU1 trial testing ivonescimab bladder cancer treatment combining PD-1 and VEGF blockade with an antibody-drug conjugate.

Kymera's KT-621 atopic dermatitis trial closes enrollment six months early, accelerating topline readout to year-end 2026.

NewAmsterdam Pharma's obicetrapib cholesterol drug wins CHMP backing for EU authorization, with a 23% MACE reduction across Phase 3...

FDA accepts daraxonrasib application for RAS-mutant pancreatic cancer, following Phase 3 data showing 13.2-month median overall survival versus 6.7...

Lexeo Therapeutics' LX2020 receives FDA RMAT designation for PKP2 cardiomyopathy, enabling expedited development and agency dialogue for the gene...